UNSPSC 51372017: Pholcodine

This classification denotes an opioid receptor agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LPP64AWZ7L. European Medicines Agency schedules Pholcodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09795MIG. Pholcodine generally arises in the molecular formula C23H30N2O4. The term PHOLCODINE is an International Non-Proprietary Name or INN. PHOLCODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule pholcodine under HS 29391100 and SITC 54141. As of Q4 2014, PHOLCODINE remains the US FDA Preferred Term for this commodity. Pholcodine bears US NLM identifiers UMLS ID C0070742 and NCI Concept Code C87365. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(OCCN1CCOCC1)CC3)C=CC2O.

UNSPSC 51372017 Pholcodine is a Commodity code, but the single recent state and local opportunity tagged under it — Seminole County, Florida's IFB for naloxone and drug deactivation systems — does not procure pholcodine itself. This code shows no relevant recent activity in state and local procurement markets.

The Seminole County solicitation, released June 30, 2026, with a response deadline of July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB structure, E-Verify compliance requirements, and potential FEMA funding suggest a health and emergency-response use case. However, pholcodine — a cough suppressant — bears no relationship to naloxone (an opioid antagonist) or drug deactivation systems. Without additional recent opportunities under this code, no broader issuing-body pattern, geographic concentration, or procurement trend can be established.